Last reviewed · How we verify
Androgen deprivation treatment — Competitive Intelligence Brief
phase 2
Hormone antagonist
Androgen receptors
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Androgen deprivation treatment (Androgen deprivation treatment) — baotai Liang. Androgen deprivation treatment drugs work by reducing the production of androgens, such as testosterone, which can fuel the growth of certain types of cancer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Androgen deprivation treatment TARGET | Androgen deprivation treatment | baotai Liang | phase 2 | Hormone antagonist | Androgen receptors |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Hormone antagonist class)
- baotai Liang · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Androgen deprivation treatment CI watch — RSS
- Androgen deprivation treatment CI watch — Atom
- Androgen deprivation treatment CI watch — JSON
- Androgen deprivation treatment alone — RSS
- Whole Hormone antagonist class — RSS
Cite this brief
Drug Landscape (2026). Androgen deprivation treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/androgen-deprivation-treatment. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab